12. Cancers in 2010 attributable to ionising radiation exposure in the UK by Parkin, D M & Darby, S C
12.
Cancers in 2010 attributable to ionising radiation exposure
in the UK
DM Parkin*,1 and SC Darby
2
1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK;
2Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, Oxford, UK
British Journal of Cancer (2011) 105, S57–S65; doi:10.1038/bjc.2011.485 www.bjcancer.com
& 2011 Cancer Research UK
                
The hazards of exposure to some types of ionising radiation were
recognized shortly after the discovery of the X-ray in 1895: by 1902
the first radiation-associated cancer was reported in a skin sore
and, within a few years, a large number of such skin cancers had
been observed. The first report of leukaemia in radiation workers
appeared in 1911. Since then there have been many reviews of the
health effects of ionising radiation, most notably in the reports of
the United Nations Scientific Committee on the Effects of Atomic
Radiation (UNSCEAR) (see, for example, UNSCEAR, 2006). The
International Agency for Research on Cancer’s Monographs on the
Carcinogenic Risk to Humans also reviewed the effects of ionising
radiation, both in the form of exposure to external g or X-rays
(IARC, 2000) and as a and b particles from internalised radio-
nuclides (IARC, 2001), and all these types of radiation were
classified as carcinogenic to humans.
The UK Health Protection Agency (HPA) reviews exposure to
ionising radiation among the population of the UK from sources of
both natural and artificial origin. A summary of their most recent
evaluation is shown in Table 1. Quantitatively, radon was the most
important source and contributed about half the total, followed by
other sources of natural radiation (cosmic, gamma and internal)
contributing about 35%, and medical radiation (which included
radiation received during diagnostic procedures, but excluded
therapeutic irradiation) at 15%.
In the present report we have estimated the number of cancers
attributable to ionising radiation in the population of the UK in
2010. We have considered the sources of exposure included in the
HPA’s review and, in addition, we have estimated the number of
second cancers associated with therapeutic radiation.
METHODS AND RESULTS
Radon
The chemically inert gas radon-222 arises from the uranium-238
present throughout the earth’s crust and is a ubiquitous air
pollutant. If inhaled, radon itself is mostly exhaled immediately,
but its short-lived progeny are solid and tend to deposit on the
bronchial epithelium, where they may expose sensitive cells to
alpha irradiation. Radon has been classified as carcinogenic to
humans (IARC, 2001). Outdoor radon concentrations in the UK
are low, but indoor concentrations are higher, especially in houses
and other small buildings, and indoor radon at home is the largest
source of exposure to natural ionising radiation. Gray et al (2009)
used information on the distribution of measured radon gas
concentrations in UK homes from a nationwide representative
survey (Wrixon et al, 1988) together with estimates of the
percentage increase in the risk of lung cancer per 100Bqm
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increase in the long-term average radon concentration at home, in
people with well-documented smoking histories (Darby et al, 2005,
2006) to estimate the burden of fatal radon-induced lung cancer in
the UK in 2006.
Table 2a shows the results from Gray et al (2009). Table 2b
shows the estimated number of cases of lung cancer caused by
radon in 2010, based on the number of deaths in Table 2a and the
total number of deaths from lung cancer in the UK in 2006 (by age
group and sex). It assumes that the fraction of lung cancer cases
due to radon is the same as the fraction of lung cancer deaths (that
is, that the risk of death from lung cancer in lung cancer patients is
the same in radon-induced cases and other cases).
The 1376 cases of lung cancer attributable to residential radon
represent 3.4% of the total number of lung cancer cases estimated
to have occurred in the UK in 2010 (or 0.4% of all new cancers in
2010). Of these, 57% of the radon-induced cancers occurred in
individuals aged 55–74 years. Most of the remainder occurred in
individuals aged over 75, with 3% at ages o55 (Table 2b). Of the
radon-induced lung cancers, 55% were in men. The vast majority
of radon-induced lung cancers are caused jointly by radon and
active smoking in the sense that the lung cancer could have been
avoided by avoiding either exposure; radon alone was estimated to
be responsible for only 157 deaths in 2006 (0.5% of lung cancer
deaths) (Gray et al, 2009). This is equivalent to 182 cases in 2010
(0.45% of lung cancer cases, 0.06% of all cancers).
Medical exposures
Medical exposures to ionising radiation include those for
diagnostic (X-rays and nuclear medicine) and therapeutic
purposes (radiotherapy). Although we are concerned here with *Correspondence: Professor DM Parkin; E-mail: d.m.parkin@qmul.ac.uk
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cancer cases likely to be induced by such radiation – these should
be set in the context of the substantial benefits accruing through
the management of individual patients.
Diagnostic X-rays Diagnostic X-rays are the largest man-made
source of radiation exposure to the general population, contribut-
ing about 15% of the total annual dose in the UK from all sources
(see Table 1). Although diagnostic X-rays provide great benefits,
their use involves a small risk of developing cancer. Berrington de
Gonza ´lez and Darby (2004) estimated the extent of this risk on the
basis of the annual number of diagnostic X-rays undertaken in the
UK. They combined data on the frequency of diagnostic X-ray use
in 1991–1996, the estimated radiation doses from X-rays to
individual body organs, and risk models (based mainly on the
Japanese atomic bomb survivors, see UNSCEAR, 2000), with
population-based cancer incidence rates from the UK in 1988–92.
They estimated the attributable fraction of cases for nine types of
cancer, and for all radiation-inducible cancers (i.e., all cancers
except lymphomas, multiple myeloma, and chronic lymphocytic
leukaemia (CLL)). In their analysis, the cumulative risks (and
attributable fractions) were calculated up to age 75. But, under the
assumption that radiation-induced cancer risks persist indefi-
nitely, the same population-attributable fractions (PAFs) should be
applicable to cases occurring after age 75.
Applying the PAFs calculated on the basis of radiation exposure
in the mid-1990s to the cancers diagnosed in the UK in 2010
(Table 3) suggests that some 1861 cases, or 0.6% of all cancers,
were caused by diagnostic radiation.
Nuclear medicine Small amounts of radiation are received
through administration of radio-isotopes for diagnostic or
therapeutic purposes. Three surveys of the frequency of different
nuclear medicine procedures in the UK and the annual collective
dose arising from them have been carried out by the HPA. Based
on the most recent survey, which was carried out in 2003–4, the
estimated total annual collective dose from diagnostic nuclear
medicine procedures was 1620 man Sv, which was approximately
32% higher than at the time of the second survey in 1989, and 67%
higher than at the time of the first survey in 1982 (Hart and Wall,
2005). The 2003–4 survey was the first to consider doses from
therapeutic nuclear medicine procedures, and the estimated
annual collective dose to the UK population from treatment of
the three commonest disorders (thyroid carcinoma, thyrotoxicosis
and non-toxic goitre) was 742 man Sv. The procedures with the
largest contributions to estimated collective dose (450 man Sv) in
2003–4 are shown in Table 4.
The doses to different organs of the body can be estimated on
the basis of the total administered activity for different procedures
and conversion factors using estimates of the dose to different
organs per unit activity administered. The estimates were taken
from publications of the International Commission on Radiologi-
cal Protection (ICRP, 1988, 1998). Thus, for example, the effective
dose of
99Tc
m phosphates is 5.7 10
 3mSvMBq
 1, while the dose
to the bladder is 4.8 10
 2mSvMBq
 1 (in adults). We may
therefore estimate the annual collective bladder dose in UK in
2003–4 as 601 (0.048/0.0057) or 5061 man Sv.
Organ-specific dose estimates were prepared for 2003–4, 1989
and 1982, with linear interpolation for the intervening years. For
years prior to 1982, we assumed the same organ-specific dose
profile as in 1982, with a linear diminution in exposure back to
zero in 1950, the period around which diagnostic radio isotopes
were coming into medical use in UK. For the years 2005–10, we
assumed the same organ-specific dose profile as in 2003–4, with
the same linear change in exposure as observed in the period
1989–2003/4.
Figure 1 shows the estimated annual collective dose for five
specific organs and also the corresponding effective dose to the
whole body. These collective doses for the whole population have
been converted to average doses for individuals in each age and sex
group in the population by multiplying the collective doses by
weights proportional to the distribution of exposure in the
different age and sex groups, and then dividing by the number
of people in the appropriate population at risk. The age and sex
distribution of exposures to radioactive isotopes in nuclear
medicine is not known; therefore, as a proxy, we assume that it
is proportional to the distribution of new cases of cancer in the
relevant time period. This is because most investigations occur in
the context of chronic disorders (including, very often, suspected
Table 2b Estimated lung cancer cases in 2010 attributable to residential
radon in the UK by age and sex
Number of cases
Age (years) Males Females Total number (%)
o35 0 1 1 (o0.1)
35–54 20 21 41 (3)
55–74 436 342 778 (57)
X75 302 254 556 (40)
All ages 759 618 1376 (100)
Table 1 Summary of the Health Protection Agency’s review of the
annual exposure of the UK population from all sources of ionising radiation
Source Average annual dose (lSv)
a Total (%)
Natural
Cosmic 330 12
Gamma 350 13
Internal 250 9.5
Radon
b 1300 50
Artificial
Medical (diagnostic only) 410 15
Occupational 6 0.2
Fallout 6 0.2
Discharges 0.9 o0.1
Consumer products 0.1 o0.1
Total (rounded) 2700 100
Based on Hughes et al (2005).
aThroughout this report the term ‘dose’ is used to
indicate ‘committed effective dose’ unless otherwise specified. ‘committed effective
dose’ is derived by considering the absorbed dose (in joules per kilogram) and then
multiplying it by a weighting factor to take account of the type of radiation involved.
For sources that do not involve a uniform dose to the whole body, the doses
to specific organs are further weighted according to factors recommended by the
International Commission on Radiological Protection (ICRP, 2007).
bAssuming that
living for a year in a home with a long-term average radon gas concentration of
20Bqm
 3 gives rise to a dose of about 1000mSv.
Table 2a Lung cancer deaths in 2006 attributable to residential radon
exposure in the UK
Number of deaths
Age (years) Males Females Total
o35 E0.5 E0.5 1
35–54 35 29 64
55–74 312 216 528
X75 290 227 517
All ages 637 473 1110
From Gray et al (2009).
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equivalent to the census at the mid-year.
Figure 2 shows the estimated average individual effective dose to
the whole body, in mSv, in 1982 and 2003–4 for males and females
combined.
As we wish to estimate the effect of these estimated annual doses
on cancer incidence in 2010, we estimated cumulative dose for
specific age groups in 2005, thereby assuming a minimum 5-year
latency between exposure and effect, as in BEIR VII (NRC, 2006).
Cumulative exposures are small: o1mSv before age 60, for
example, and only about 6.5mSv (males) and 4mSv (females) by
age 90. To estimate the effects of such radiation for cancers other
than leukaemia, we used the cancer risk estimates, expressed as
excess relative risks (ERRs) per Sv, from the report of UNSCEAR
(2006) as summarised in Table 5.
The ERRs in 2005, together with the estimated doses, were
applied to the observed numbers of solid cancer cases in 2010, to
obtain the attributable cancers. The total was small – only about 4
excess cases in each sex.
For leukaemia, the relationship between risk and exposure is
more complex, as ERR depends not only on dose but also on age at
exposure, and time since exposure, and varies by sex. The BEIR
VII report (NRC, 2006) used a model that expressed ERR as a
linear-quadratic function of dose, with allowance for dependencies
on sex, age at exposure and time since exposure. The preferred
model took the form:
ERR ¼ bDð1 þ yDÞexp½ge  þ dlogðt=25Þþfe logðt=25Þ 
where D is the dose (Sv), t is the time since exposure (years),
e*¼(e 30)/10 for eo30, and ¼0 for eX30, where e is age at
exposure in years; b¼1.1 for males, 1.2 for females; g¼ 0.40 per
decade (of age at exposure); d¼ 0.48; f¼0.42; and y¼0.87.
Table 3 Estimated cancer cases in the UK in 2010 by caused by diagnostic radiation
Males Females
Cumulative risk at
ages 0–74 (%)
a
Number of cases in
2010 at all ages
Cumulative risk at
ages 0–74 (%)
a
Number of cases in
2010 at all ages
Cancer
Radiation
induced Population
PAF
(%)
Observed
cases
Excess
attributable
cases
Radiation
induced Population
PAF
(%)
Observed
cases
Excess
attributable
cases
Oesophagus 0.002 0.67 0.3 5713 17 0.002 0.33 0.6 2819 17
Stomach 0.006 1.33 0.5 4467 20 0.005 0.55 0.9 2577 23
Colon-rectum 0.014 1.56 0.9 22127 199 0.026 1.45 1.8 17787 319
Liver 0.001 0.18 0.6 2270 13 0.001 0.09 1.1 1298 14
Lung 0.007 5.50 0.1 22273 28 0.013 2.46 0.5 18132 96
Female breast — — — 0 0 0.009 6.77 0.1 48385 62
Bladder 0.034 1.70 2.0 6713 134 0.009 0.56 1.7 2572 43
Thyroid o0.001 0.06 0.4 602 2 0.001 0.15 0.8 1776 14
Leukaemia (excluding CLL) 0.008 0.60 1.3 3002 40 0.008 0.42 1.9 2182 42
All above 0.072 11.60 0.6 67167 453 0.074 12.77 0.6 97528 630
Other radiation-inducible 0.051 8.80 0.6 79828 462 0.052 8.06 0.6 48994 316
All cancers
b — — 0.6 158667 915 — — 0.6 155584 946
Abbreviations: CLL¼chronic lymphocytic leukaemia; PAF¼population-attributable fraction.
aCumulative risks, based on exposures in 1991–6, from Berrington de Gonza ´lez
and Darby (2004).
bExcluding non-melanoma skin cancer.
Table 4 Nuclear medicine procedures and estimated radiation doses
Isotope
Average
dose
per
procedure
(mSv)
Annual
collective
dose
2003–4
(man Sv)
Diagnostic
Bone scan
99Tc
m Phosphates 3.0 601
Myocardium
201Tl Thallous chloride 12.9 209
Myocardium
99Tc
m Tetrofosmin 3.1 196
Myocardium
99Tc
m Sestamibi 3.7 92
Lung perfusion
99Tc
m MAA 0.9 85
Tumours (PET)
18F FDG 7.0 83
Therapeutic
Thyroid carcinoma
131l Iodide 259.0
a 437
Thyrotoxicosis and goiter
131l Iodide 29.0
a 305
Abbreviations: mSv¼milli-Sievert; man Sv¼man-Sievert. Based on Hart and Wall
(2005).
aExcludes dose to the thyroid.
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Figure 1 Estimated annual collective doses from nuclear medicine, for
five specific organs and for the whole body. The estimate for the whole
body is a weighted average of the estimates for specific organs, using the
tissue-weighting factors recommended by the ICRP. These were chosen to
represent approximately the relative contributions from different organs to
the total number of radiation-induced cancers that would arise following
uniform irradiation of the whole body (ICRP, 2007).
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exposure. Therefore, the formula is used to calculate ERR in each
age group, assuming annual doses estimated as described above,
starting at those aged 5–9 years in 2010, who would have been first
exposed at a mean age of 2.5. The BEIR VII committee (NRC, 2006)
dealt with recent exposures by assuming that the excess absolute
risk in the period 2–5 years following exposure is equal to that
observed 5 years after exposure. Therefore, for the youngest age
group (0–4 years), we derived the ERR by assuming that the excess
absolute risk was the same as that for children aged 5–9 years who
had been exposed at (mean) age 2.5. As exposures are assumed to
have been occurring since 1950, we assume that the relative risks in
each 5-year age group are multiplicative. That is, the relative risk
in children aged 10–14 years in 2010 is the product of that in
children exposed for 5 years at (mean) age 7.5 and that in children
exposed for 10 years at (mean) age 2.5. As in the BEIR VII report
(NRC, 2006), we assumed that the risk of CLL is not influenced by
exposure to radiation, so the estimated ERRs were applied to the
number of leukaemia cases in the UK, excluding CLL. The
proportions of CLL cases among all leukaemia were taken from the
published data for England for 2007 (ONS, 2010). We estimate that
7.7 cases of leukaemia in males (0.17% of all leukaemia) and 4.5 in
females (0.14% of leukaemia cases) might be attributable to
exposures received through nuclear medicine.
Adding the solid cancers and leukaemia cases, the total estimate
for cancers attributable to radiation received through nuclear
medicine exposures in 2010 is 11.5 in males (0.007% of all cancers)
and 7.9 cancers in females (0.005% of all cancers).
Therapeutic radiation Around 3% of the UK population are
cancer survivors, with the total number now around 2 million and
increasing by 3% per annum (Maddams et al, 2009). Many cancer
survivors have received radiotherapy, and such treatment usually
involves some incidental irradiation of the surrounding normal
tissues, thus increasing the risk of a radiation-associated second
cancer. Up until now, estimates of the radiation exposure of the
UK population have not included exposure from radiotherapy, and
the total number of cancers in the UK population associated with
past radiation exposure from radiotherapy has not been assessed
previously.
Maddams et al (2011) have prepared estimates of the cancer
burden in the UK in 2007 due to radiotherapy. The method used
was based on estimates of the numbers of cancer survivors in the
UK at the beginning of 2007 (by cancer site, sex, age and time since
diagnosis), the proportion that had received treatment by radio-
therapy, and the relative risk of a second cancer associated with
previous radiotherapy (from the United States Surveillance
Epidemiology and End Results (SEER) programme (Curtis et al,
2006)). The methodology for preparing estimates of the number of
cancer survivors for England is described in Maddams et al (2009);
age- and sex-specific population ratios between England and the
UK were then used to scale these numbers to a UK level. The
radiotherapy proportions from the Thames Cancer Registry were
applied to the estimated numbers of cancer survivors in the UK at
the beginning of 2007 to provide an estimate of the number who
had, and the number who had not, received radiotherapy, by sex,
age, cancer site and time since diagnosis (in periods o1, 1–4, 5–9,
10–14, 15–19, 20–35 years). The numbers of second cancers
associated with radiotherapy were estimated for 13 cancer sites,
based on the risk, relative to the general population (of the
SEER registry areas), of developing a second cancer, for intervals
o1, 0–4, 5–9 and 10þ years post diagnosis of the first cancer, for
cancer survivors who had received radiotherapy (Rrtþ) and those
who had not (Rrt ). The excess risk of cancer due to radiotherapy,
relative to the general population (ERR), is then given by
ERR ¼ Rrtþ   Rrt 
For each of the 13 cancer sites, the numbers of second cancers
expected in the UK during 2010 associated with radiotherapy for a
previous cancer were estimated using incidence rates for 2010 in
the UK population and the relative risk of a second cancer in
cancer survivors. To estimate the total number of second cancers,
the numbers estimated to have occurred among survivors of the 13
selected cancer sites were multiplied by the ratio of the number of
cancer survivors for all cancers combined to that for just the 13
selected sites combined, by sex, age group and time since
diagnosis.
Table 6 shows estimates of the numbers of second cancers (all
malignant neoplasms excluding non-melanoma skin cancer)
diagnosed in the UK in 2010 among people who had previously
been diagnosed with one of the 13 selected sites of the initial
cancer.
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Figure 2 Average individual effective dose to the whole body (mSv),
from nuclear medicine practice, 1982 and 2003–4, males and females
combined.
Table 5 Excess relative risk (% per Sievert)
Excess relative risks (% per Sievert) by cancer and sex
Oesophagus Stomach Colon Liver Lung Bone Breast Bladder
Brain
and CNS Thyroid
All other
solid cancers
MF M F M F M F M F M F M F M F M F M F M F
0.68 0.39 0.44 0.21 1.44 1.21 0.16 0.11 2 4.93 0.19 0.14 — 8.88 2.08 0.73 0.41 0.29 0.16 0.44 3.87 2.4
Abbreviations: CNS, central nervous system; F, female; M, male. Based on United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) Table 71 (2006).
Excess relative risk¼relative risk 1.
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cancers diagnosed in male survivors and 10766 in female survivors
and that, of these, 328 (5.6%) in men and 866 (8.0%) in women
were associated with radiotherapy. These second cancers exclude
those at the same site as the first, except for cancers of the oral
cavity and pharynx, colon–rectum and contralateral breast.
The greatest number of second cancers in the UK in 2010 was
among female survivors of breast cancer – 7429 cancers, of which
626 (8.4%) were associated with radiotherapy for the initial breast
cancer; these represent 52.4% of the 1194 radiotherapy-associated
cancers occurring among survivors of the 13 sites considered.
There were also relatively large numbers of cancers occurring
among survivors of colorectal cancer (2999: i.e., 1751 in males and
1248 in females) and prostate cancer (2006), although the
percentages of these that were associated with radiotherapy were
relatively small (2.2% and 5.1%, respectively). Of the second
cancers that occurred among survivors of cancer of the oral cavity
and pharynx, cervix uteri, and Hodgkin lymphoma, over 15% were
estimated to be associated with radiotherapy for the first cancer.
Table 7 summarises the estimated numbers of cancers at
different sites occurring in 2010 among the survivors of cancer at
any of the 13 selected sites considered, and the numbers of these
associated with radiotherapy. The most important among those
estimated to be radiation-associated, in terms of numbers of cases,
are cancers of the lung (274), oesophagus (159) and female breast
(129). In all, 14.7% of second lung cancers were associated with
radiotherapy, as were 31.1% of the oesophageal cancers. However,
only 3.3% of breast cancers occurring in cancer survivors were
radiotherapy-associated.
Table 8 (left-hand columns) shows the distribution of radio-
therapy-related second cancers in 2010, in survivors of one of the
13 cancers considered, by age group and sex. The numbers are
expressed as a percentage of all second cancers, and as a
percentage of all cancers registered in the UK population. It also
shows (right-hand columns) the estimated total number of
radiotherapy-related second cancers occurring: 430 cases in men
(0.26% of all new cancer cases) and 950 cases in women (0.60% of
all new cancers).
Other forms of natural background radiation
As noted in Table 1, apart from radon, ionising radiation exposure
comes naturally from cosmic rays, followed by terrestrial sources
of gamma radiation, and ‘internal’ emissions.
Cosmic rays are particles that travel through interstellar space.
The sun is a source of some of these particles; others come from
exploding stars (supernovas). Exposure is increased by air travel at
high altitudes.
The amount of terrestrial radiation from rocks and soils varies
geographically depending on their local content of uranium.
‘Internal’ emissions come from radioactive isotopes in food and
water and from the human body itself. Exposures from eating and
drinking are due in part to the uranium and thorium series of
radioisotopes present in food and drinking water. Carbon-14 is
present in all living things, and accumulates in the food chain and
Table 6 Total numbers of second cancers expected in the UK in 2010,
and those associated with the excess risk of cancer due to previous
radiotherapy, by site of first cancer (13 selected cancer sites)
First cancer type
Expected number
of second cancers
a
Number (%) associated
with radiotherapy
for first cancer
Males
Oral cavity and pharynx 243 47 (19.3)
Oesophagus 85 8 (9.8)
Stomach 177 1 (0.7)
Colorectal 1751 44 (2.5)
Larynx 391 32 (2.5)
Lung 422 33 (7.7)
Prostate 2006 103 (5.1)
Testes 217 23 (10.8)
Hodgkin lymphoma 218 34 (10.8)
Non-Hodgkin lymphoma 391 2 (0.4)
Total (above 10 sites) 5899 328 (5.6)
Females
Oral cavity and pharynx 120 20 (16.6)
Oesophagus 45 6 (12.7)
Stomach 74 0 (0.4)
Colorectal 1248 22 (1.7)
Larynx 51 4 (1.7)
Lung 150 8 (5.1)
Breast 7429 626 (8.4)
Cervix uteri 526 90 (17.1)
Corpus uteri 691 61 (8.9)
Hodgkin lymphoma 145 28 (19.2)
Non-Hodgkin lymphoma 286 1 (0.4)
Total (above 11 sites) 10766 866 (8.0)
aSecond cancers exclude those at the same site as the first, except for oral cavity and
pharynx, colorectal and contralateral breast cancers. Also excluded are all leukaemias
diagnosed within one year of any first cancer and all second cancers of other sites
diagnosed within 5 years of any first cancer.
Table 7 Expected number of second cancers in 2010, by site of second
cancer, in survivors of selected primary cancers,
a and those associated with
the excess risk of cancer due to radiotherapy for the initial cancer
Second cancer type
a
Expected number
of second cancers
b
Number (%) associated
with radiotherapy
for first cancer
Males
Oral cavity and pharynx 179 18 (9.9)
Oesophagus 280 74 (26.3)
Stomach 178 14 (7.7)
Colorectal 836 25 (3.0)
Pancreas 146 3 (2.0)
Larynx 57 4 (7.6)
Lung 859 86 (10.0)
Melanoma of the skin 154 4 (2.8)
Prostate 751 0 (0.0)
Bladder 318 23 (7.2)
Leukaemia 256 0 (0.0)
Other sites 1886 77 (4.1)
All
c 5899 328 (5.6)
Females
Oral cavity and Pharynx 132 1 (0.8)
Oesophagus 232 85 (36.6)
Stomach 170 19 (11.0)
Colorectal 1040 48 (4.6)
Pancreas 222 10 (4.4)
Lung 1003 188 (18.8)
Melanoma of the skin 238 43 (17.9)
Breast 3905 129 (3.3)
Cervix 30 2 (7.9)
Corpus uteri 377 35 (9.3)
Ovary 298 12 (4.1)
Bladder 187 15 (7.9)
Leukaemia 218 39 (18.1)
Other sites 2712 240 (8.8)
All
c 10766 866 (8.0)
aPrimary cancers as listed in Table 6.
bSecond cancers exclude those at the same site
as the first, except for oral cavity and pharynx, colorectal and contralateral breast
cancers. Also excluded are all leukaemias diagnosed within one year of any first
cancer and all second cancers of other sites diagnosed within 5 years of any first
cancer.
cExcluding non-melanoma skin cancer.
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radiation.
In estimating the effects of such radiation, we make the
simplifying assumption that exposure is uniform throughout the
body (rather than concentrated in specific organs), and use the
cancer risk estimates, expressed as ERR per unit exposure, from
the report of UNSCEAR (2006), as shown in Table 5.
Assuming an average annual dose of 0.93mSv (Table 1), and a
minimum 5-year latency between exposure and the increased risk
of solid cancers, the excess incidence of solid cancers (i.e.,
excluding leukaemias) in the UK in 2010 is shown in Table 9. The
total is 609 cases (or 0.2% of all cancers).
For leukaemia, we used the formula for ERR from BEIR
described above in the section on Nuclear Medicine to calculate the
relative risk in each age group, assuming an annual exposure of
0.93mSv, starting at those aged 5–9 years in 2010, who would have
been first exposed at a mean age of 2.5. For the youngest age group
(0–4 years), we assumed that the excess absolute risk was the same
as that for children aged 5–9 years who had been exposed at
(mean) age 2.5 (see above). As exposure is continuous throughout
life (rather than a single exposure to radiation at a given age), we
assume that the risks in each 5-year age group are multiplicative
(i.e., the risk in children aged 10–14 years in 2010 is the product of
that in children exposed for 5 years at (mean) age 7.5 and of that in
children exposed for 10 years at (mean) age 2.5). The estimated
relative risks were applied to the number of leukaemia cases in the
UK, excluding CLL.
We estimate that 316 cases of leukaemia in males (6.8% of all
leukaemia) and 245 in females (7.7% of leukaemia cases) might be
attributable to background radiation. Of these, 81 cases occurred
in children aged o15 years (16.6% of leukaemia cases in this age
group).
Adding the solid cancers and leukaemia cases, the total estimate
is of 553 radiation-attributable cancers in males (0.35% of all
cancers) and 617 cancers in females (0.40% of all cancers).
Summary of results
Table 10 shows the sum of the estimated numbers of cancers
resulting from exposure to radon, to other forms of natural
background radiation and from man-made sources: diagnostic
radiology, radiotherapy and nuclear medicine.
In total, we estimate that approximately 5807 of the cancers
diagnosed in the UK in 2010 were the result of such exposures, or
around 1.8% of the total.
DISCUSSION
With respect to cancer causation, these calculations suggest that
diagnostic radiology is the most important source of ionising
radiation in the UK population. Our estimates are based on the
work of Berrington de Gonza ´lez and Darby (2004), whose
estimates may be slightly high as they assumed that the life
expectancy of individuals undergoing diagnostic radiology was the
same as that of the general population. Any such overestimation is,
however, small compared with the likely underestimation due to
the application of risks based on exposures 15 years earlier to
calculate the attributable fraction of cancers caused by diagnostic
radiation occurring in 2010. For solid cancers, radiation-related
excess risk starts to appear about 5 years after exposure in
Table 8 Expected number of second cancers in the UK in 2010 associated with radiotherapy for a previous cancer, by age and sex
Among survivors of 13 selected cancers
a Among all cancer survivors
Age group (years) Number % of second cancers % of all cancers
b Number % of all cancers
b
Males
0–34 0 4.7 0.01 1 0.02
35–44 2 9.5 0.05 3 0.08
45–54 9 10.9 0.08 12 0.11
55–64 36 9.0 0.11 45 0.14
65–74 82 6.0 0.16 100 0.19
X75 199 4.9 0.33 269 0.44
All ages 328 5.6 0.20 430 0.26
Females
0–34 0 7.1 0.01 1 0.02
35–44 4 6.4 0.05 6 0.07
45–54 29 6.6 0.15 34 0.18
55–64 137 7.5 0.44 150 0.48
65–74 255 8.7 0.68 277 0.74
X75 440 8.0 0.79 482 0.87
All ages 866 8.0 0.55 950 0.60
aPrimary cancers as listed in Table 6.
bExcluding non-melanoma skin cancer.
Table 9 Excess incidence of solid cancers in 2010 due to background
radiation in the UK
Males Females
Cancer
Excess
attributable cases
PAF
(%)
Excess
attributable cases
PAF
(%)
Oesophagus 2.4 0.04 0.7 0.03
Stomach 1.2 0.03 0.3 0.01
Colorectum 19.6 0.09 13.5 0.08
Liver 0.2 0.01 0.1 0.01
Lung 27.7 0.12 55.6 0.31
Bone o0.1 0.01 o0.1 0.01
Female breast — — 235.5 0.49
Bladder 9.0 0.13 1.2 0.05
Brain and CNS 0.6 0.02 0.3 0.01
Thyroid o0.1 0.01 0.3 0.02
All other solid
a 176.6 0.23 64.2 0.14
All solid
a 237.3 0.15 371.9 0.24
Abbreviations: CNS¼central nervous system; PAF¼population-attributable frac-
tion.
aExcluding non-melanoma skin cancer.
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while for leukaemia, the increase in risk following exposure
certainly starts to appear within 5 years of exposure (Darby et al,
1987); therefore, a more appropriate period of exposure would be
some 5–10 years earlier (i.e., 2000–5). The use of X-rays –
particularly of computerised tomography (CT) scans, which result
in higher organ doses of radiation than conventional single-film X-
rays – has certainly increased between the period for which
Berrington de Gonza ´lez and Darby (2004) obtained detailed
information on X-ray procedures (1991–6) and 2005. A recent
report from the Health Protection Agency (Hart et al, 2010)
estimated that the per caput dose from diagnostic radiology was
about 400mSv in 2008, compared with about 330mSv in 1997–8.
The increase is due mainly to the increasing use of CT
examinations, which by 2008 accounted for 68% of the collective
dose from all medical and dental X-ray examinations.
Radiation therapy is probably the second most important source
of radiation-associated cancer (about one-quarter of the 5807
radiation-attributable cancers). Maddams et al (2011) provide a
full discussion of the assumptions and limitations of the
estimation, which include the following:
  The total number of survivors in the UK (i.e., the population at
risk of a second cancer) is slightly underestimated, as the
estimate used includes only those survivors diagnosed up to 35
years previously, although these account for 95% of all
survivors.
  The UK prevalence of individuals with a past diagnosis of
cancer who have, or have not, received radiotherapy was
inferred from the proportions of cancer survivors who are
recorded as having received radiotherapy in the database of the
Thames Cancer Registry, and it was assumed that these
proportions are reasonably representative of the national
situation.
  The estimate of the relative risk of second cancers in survivors
who had, and had not, received radiotherapy was derived from
the experience of cancer patients in the US SEER population
between 1973 and 2000. As radiation treatment was not
randomised, selection bias could have resulted in differences
between treatment groups with regard to other factors that
affect second cancer risk – for example, smoking status, the
clinical and pathological features of the initial cancer or
concomitant disease.
  It was assumed that the nature of radiotherapy treatment for a
given cancer was broadly similar in the US and the UK in the
same time period (diagnosis of the initial cancer in 1973–2000).
  Estimation was based on data on prevalence and relative risk of
radiotherapy for 13 specific cancer types, and the estimate for
all cancer survivors involved a further assumption: that the rate
of radiation-associated cancers among the sites not considered
Table 10 Summary of estimated number of cancers in 2010 caused by exposure to ionising radiation, UK
Excess attributable cases
Total excess attributable cases PAF (%)
Type of cancer Background Radon Diagnostic radiology Radiotherapy Nuclear medicine All radiation
Males
Oesophagus 2 — 17 97 0.0 116 2.0
Stomach 1 — 20 18 0.0 39 0.9
Colon-rectum 20 — 199 33 0.3 252 1.1
Liver 0 — 13 — 0.0 13 0.6
Lung 28 759 28 113 0.5 928 4.2
Breast (female) — — — — — — —
Bladder 9 — 134 30 1.3 174 2.6
Thyroid 0 — 2 — 0.0 2 0.4
Leukaemia 316 — 40 0 7.7 364 7.8
Other 177 — 462 140 1.6 780
All
a 553 759 915 430 11.5 2669 1.7
Females
Oesophagus 1 — 17 93 0.0 111 3.9
Stomach 0 — 23 21 0.0 44 1.7
Colon—rectum 14 — 319 53 0.0 385 2.2
Liver 0 — 14 — 0.0 15 1.1
Lung 56 618 96 206 0.8 976 5.4
Breast (female) 235 — 62 141 1.9 440 0.9
Bladder 1 — 43 16 0.1 60 2.3
Thyroid 0 — 14 — 0.0 15 0.8
Leukaemia 245 — 42 43 4.5 334 10.4
Other 65 — 316 376 0.5 757 —
All
a 617 618 945.5 950 7.9 3138 2.0
Persons
Oesophagus 3 — 34 190 0 227 2.7
Stomach 2 — 44 39 0 84 1.2
Colon—rectum 33 — 518 86 0 637 1.6
Liver 0 — 27 0 0 27 0.8
Lung 83 1376 124 319 1 1905 4.7
Breast (female) 235 — 62 141 2 440 0.9
Bladder 10 — 177 46 1 235 2.5
Thyroid 0 — 17 0 0 17 0.7
Leukaemia 561 — 82 43 12 698 8.9
Other 242 — 778 516 2 1537 0.0
All
a 1170 1376 1861 1380 19 5807 1.8
Abbreviation: PAF¼population-attributable fraction.
aExcluding non-melanoma skin cancer.
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in women) was similar to that among those that were.
In addition, the estimate for 2010 is based on the assumption
that the prevalence of cancer at the beginning of 2010 was the same
as at the beginning of 2007 (as in Maddams et al, 2011). In fact, it is
likely that prevalence would have increased somewhat in the
intervening 3 years, due to increasing incidence, especially of
cancers with a good prognosis (breast, large bowel, prostate), and
improvements in survival.
Radiotherapy may also be the cause of some other long-term
effects, such as an increased risk of cardiovascular disease.
However, any long-term side effects of radiotherapy should always
be considered in the context of the considerable benefits in terms
of control of symptoms and disease.
The estimated number of cases of lung cancer resulting from
exposure to radon includes those cases that are the consequence of
both smoking and radon exposure and, since their joint effects are
multiplicative (Darby et al, 2005), the great majority of such cases
occur in smokers, and could be avoided by smoking cessation.
Nevertheless, it has been demonstrated that policies requiring
basic preventive measures against radon in all new homes
throughout the UK would be cost effective and could complement
existing policies to reduce smoking (Gray et al, 2009). In contrast,
policies involving the identification of existing homes with high
radon levels are much less cost-effective and can do little to
prevent most radon-related deaths, as these are caused by
moderate exposure in many homes.
Most exposure to natural background radiation is not, in
practice, avoidable. It is a cause of about one in five radiation-
induced cancers, almost half of which are leukaemias. Wakeford
et al (2009) have recently published an estimate of the fraction of
childhood leukaemia cases that might be attributable to natural
background radiation. The precise result depended on the model
used to estimate risk in the UK population, based on the results of
the life span study of A-bomb survivors, but it is around 20% (in
line with an earlier estimate (Wakeford, 2004)). The result of our
rather more simplistic estimation approach (17%) is very similar,
despite the assumption that the bone marrow dose of radiation
from natural sources is constant throughout life. In fact, the
radiation dose to the bone marrow of children – especially from
ingested sources – is some 20–40% higher (depending on age)
than in adults (Kendall et al, 2009), so that our estimates (and
those of Wakeford et al, 2009) may be a little conservative. In any
event, the small contribution of childhood leukaemia to the total of
radiation-related cancer means that such adjustments will have
almost no effect on the totals in Table 10.
As we describe in the sections related to Methodology, the
estimates of population exposure levels (dose) of radiation from
the various sources considered rely on many extrapolations and
assumptions. Furthermore, we take the conventional view that the
relationship between cancer risk and dose at low levels of exposure
follows that observed at higher levels, with no threshold effect,
although there is very little direct evidence on this point. Despite
these limitations, we believe that the overall estimate of around
5000 radiation-induced cancers in the UK (about 2% of the total) is
of the correct order of magnitude.
See acknowledgements on page Si.
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